The DOI matches its Crossref record; 160 of the 160 references it cites were found in a registry or an index.
Parkinson's disease
Open accessAbstract
Parkinson's disease is a recognisable clinical syndrome with a range of causes and clinical presentations. Parkinson's disease represents a fast-growing neurodegenerative condition; the rising prevalence worldwide resembles the many characteristics typically observed during a pandemic, except for an infectious cause. In most populations, 3-5% of Parkinson's disease is explained by genetic causes linked to known Parkinson's disease genes, thus representing monogenic Parkinson's disease, whereas 90 genetic risk variants collectively explain 16-36% of the heritable risk of non-monogenic Parkinson's disease. Additional causal associations include having a relative with Parkinson's disease or tremor, constipation, and being a non-smoker, each at least doubling the risk of Parkinson's disease. The diagnosis is clinically based; ancillary testing is reserved for people with an atypical presentation. Current criteria define Parkinson's disease as the presence of bradykinesia combined with either rest tremor, rigidity, or both. However, the clinical presentation is multifaceted and includes many non-motor symptoms. Prognostic counselling is guided by awareness of disease subtypes. Clinically manifest Parkinson's disease is preceded by a potentially long prodromal period. Presently, establishment of prodromal symptoms has no clinical implications other than symptom suppression, although recognition of prodromal parkinsonism will probably have consequences when disease-modifying treatments become available. Treatment goals vary from person to person, emphasising the need for personalised management. There is no reason to postpone symptomatic treatment in people developing disability due to Parkinson's disease. Levodopa is the most common medication used as first-line therapy. Optimal management should start at diagnosis and requires a multidisciplinary team approach, including a growing repertoire of non-pharmacological interventions. At present, no therapy can slow down or arrest the progression of Parkinson's disease, but informed by new insights in genetic causes and mechanisms of neuronal death, several promising strategies are being tested for disease-modifying potential. With the perspective of people with Parkinson's disease as a so-called red thread throughout this Seminar, we will show how personalised management of Parkinson's disease can be optimised.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Strikingly, non-motor symptoms remain poorly responsive to current PD treatments despite being present from early prodromal PD and contributing significantly to overall disease burden [36].”
From The gut–brain axis in early Parkinson’s disease: from prodrome to prevention (2025) · cites this paper as [36]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Clinical practice guidelines support resilience training and exercise for patients with Parkinson’s disease (PD).”
From A randomized clinical trial of mindfulness meditation versus exercise in Parkinson’s disease during social unrest (2023) · cites this paper as [1]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The diseases encompass various severe conditions, including neurodegenerative disorders like Alzheimer’s disease (AD) [3, 4] and Parkinson’s disease (PD) [5, 6], as well as traumatic brain injuries (TBI) [7] and spinal cord injuries (SCI) [8].”
From Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions (2024) · cites this paper as [5]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED ARTICLE: Parkin and PINK1 mitigate STING-induced inflammation
Sliter, D. A., Martinez, J., Hao, L., Chen, X., Sun, N., Fischer, T. D., Burman, J. L., Li, Y., Zhang, Z., Narendra, D. P., et al. (2018) · Nature · doi:10.1038/s41586-018-0448-9 · Cited by 1,287
Self-citationRetractedStaging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
MDS clinical diagnostic criteria for Parkinson’s disease
Postuma, R. B., Berg, D., Stern, M., Poewe, W., Olanow, C. W., Oertel, W., Obeso, J., Marek, K., Litvan, I., Lang, A. E., et al. (2015) · Movement Disorders · doi:10.1002/mds.26424 · Cited by 7,653
Self-citationKalia, L. V., & Lang, A. E. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61393-3 · Cited by 6,184
Feigin, V. L., Nichols, E., Alam, T., Bannick, M. S., Beghi, E., Blake, N., Culpepper, W. J., Dorsey, E. R., Elbaz, A., Ellenbogen, R. G., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30499-x · Cited by 5,644
Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson's disease
Sampson, T. R., Debelius, J. W., Thron, T., Janssen, S., Shastri, G. G., Ilhan, Z. E., Challis, C., Schretter, C. E., Rocha, S., Gradinaru, V., et al. (2016) · Cell · doi:10.1016/j.cell.2016.11.018 · Cited by 3,622
Huber, M., Knottnerus, J. A., Green, L., van der Horst, H. E., Jadad, A. R., Kromhout, D., Leonard, B. E., Lorig, K. R., Loureiro, I., Meer, J. W. M. V. D., et al. (2011) · BMJ · doi:10.1136/bmj.d4163 · Cited by 2,983
Diagnosis and Treatment of Parkinson Disease: A Review
Armstrong, M. J., & Okun, M. S. (2020) · JAMA · doi:10.1001/jama.2019.22360 · Cited by 2,924
Self-citationDorsey, E. R., Elbaz, A., Nichols, E., Abbasi, N., Abd-Allah, F., Abdelalim, A., Adsuar, J. C., Ansha, M. G., Brayne, C., Choi, J.-Y. J., et al. (2018) · The Lancet Neurology · doi:10.1016/s1474-4422(18)30295-3 · Cited by 2,816
Nalls, M. A., Blauwendraat, C., Vallerga, C. L., Heilbron, K., Bandres-Ciga, S., Chang, D., Tan, M., Kia, D. A., Noyce, A. J., Xue, A., et al. (2019) · The Lancet Neurology · doi:10.1016/s1474-4422(19)30320-5 · Cited by 2,454
Cited by
Sorted by citations
Items 401–500 of 1,004
van Munster, M., Stümpel, J., Thieken, F., Pedrosa, D. J., Antonini, A., Côté, D., Fabbri, M., Ferreira, J. J., Růžička, E., Grimes, D., et al. (2021) · Journal of Personalized Medicine · doi:10.3390/jpm11070623 · Cited by 33
Tringali, C., & Giussani, P. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23147806 · Cited by 33
Kremer, N. I., van Laar, T., Lange, S. F., Muller, S. S., Gemert, S. L. B., Oterdoom, D. L. M., Drost, G., & van Dijk, J. M. C. (2022) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2022-329192 · Cited by 34
Psychobiotics for Mitigation of Neuro‐Degenerative Diseases: Recent Advancements
Dhyani, P., Goyal, C., Dhull, S. B., Chauhan, A. K., Saharan, B. S., Harshita, Duhan, J. S., & Gökşen, G. (2023) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202300461 · Cited by 30
Evers, L. J. W., Peeters, J. M., Bloem, B. R., & Meinders, M. J. (2023) · Frontiers in Neurology · doi:10.3389/fneur.2023.1150634 · Cited by 29
Self-citationParkinson's disease – current treatment
Wang, R. Z., & Shih, L. C. (2023) · Current Opinion in Neurology · doi:10.1097/wco.0000000000001166 · Cited by 29
Zhou, Y., Wang, Y., Wan, J., Zhao, Y., Pan, H., Zeng, Q., Zhou, X. C., He, R., Zhou, X., Xiang, Y., et al. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00571-4 · Cited by 32
Hireš, M., Drotár, P., Pah, N. D., Ngo, Q. C., & Kumar, D. (2023) · International Journal of Medical Informatics · doi:10.1016/j.ijmedinf.2023.105237 · Cited by 29
Research Progress on Effects of Ginsenoside Rg2 and Rh1 on Nervous System and Related Mechanisms
Liu, S., Chen, W., Zhao, Y. H., Zong, Y., Li, J., & He, Z. (2023) · Molecules · doi:10.3390/molecules28237935 · Cited by 29
Prevalence and Incidence of Parkinson's Disease in Latin America: A Meta‐Analysis
Kim, D. J., Isidro‐Pérez, A. L., Doering, M. M., Rodríguez, J. J. L., Acosta, I., Salgado, A. M. R., Pinilla-Monsalve, G. D., Tanner, C. M., Llibre‐Guerra, J. J., & Prina, M. A. (2023) · Movement Disorders · doi:10.1002/mds.29682 · Cited by 29
Zhao, X., Kang, Z., Han, R., Wang, M., Wang, Y., Sun, X., Wang, C., Zhou, J., Cao, L., & Lu, M. (2024) · Redox Biology · doi:10.1016/j.redox.2024.103190 · Cited by 30
Mediterranean Diet Adherence, Gut Microbiota and Parkinson’s Disease: A Systematic Review
Seelarbokus, B. A., Menozzi, E., Schapira, A. H. V., Kalea, A. Z., & Macnaughtan, J. (2024) · Nutrients · doi:10.3390/nu16142181 · Cited by 36
Rafe, M. R., Saha, P., & Bello, S. T. (2024) · Behavioural Brain Research · doi:10.1016/j.bbr.2024.115173 · Cited by 29
Interaction between resveratrol and SIRT1: role in neurodegenerative diseases
Zhu, L., Yang, M., Fan, L., Yan, Q., Zhang, L., Mu, P., & Lu, F. (2024) · Naunyn-Schmiedeberg s Archives of Pharmacology · doi:10.1007/s00210-024-03319-w · Cited by 31
Liu, J., Liang, Y., Meng, Q., Chen, J., Ma, J., Zhu, H. Y., Cai, L., Song, N., Ding, J., Fan, Y., et al. (2024) · Science Advances · doi:10.1126/sciadv.adn4845 · Cited by 31
Liang, X., Zeng, Y., Zhang, P., Zhu, B., Feng, J., Deng, T., Fu, Z., Liu, C., Chen, C., & Zhang, Y. (2025) · Journal of Translational Medicine · doi:10.1186/s12967-025-06634-9 · Cited by 41
Neurodegenerative Disorders: Spotlight on Sphingolipids
Mandik, F., & Vos, M. H. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms222111998 · Cited by 31
Zhou, X., Zhao, P., Guo, X., Wang, J., & Wang, R. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.935176 · Cited by 32
Quality of Life in Patients With Parkinson’s Disease: A Cross-Sectional Study
Al-Khammash, N., Al-Jabri, N., Albishi, A., Al-Onazi, A., Aseeri, S., Alotaibi, F., Almazroua, Y., & Albloushi, M. (2023) · Cureus · doi:10.7759/cureus.33989 · Cited by 32
Pérez-Segura, I., Santiago-Balmaseda, A., Rodríguez-Hernández, L. D., Morales-Martínez, A., Martínez-Becerril, H. A., Martínez-Gómez, P. A., Delgado-Minjares, K. M., Salinas‐Lara, C., Martínez-Dávila, I. A., Guerra‐Crespo, M., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24043264 · Cited by 29
Vielee, S. T., & Wise, J. P. (2023) · Brain Sciences · doi:10.3390/brainsci13030500 · Cited by 31
Ghislieri, M., Lanotte, M., Knaflitz, M., Rizzi, L., & Agostini, V. (2023) · Scientific Reports · doi:10.1038/s41598-023-34151-6 · Cited by 29
Natural Products as the Potential to Improve Alzheimer’s and Parkinson’s Disease
Kim, S. W., Lee, J. H., Kim, B., Yang, G., & Kim, J. U. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24108827 · Cited by 30
Disruption of locus coeruleus-related functional networks in Parkinson’s disease
Sun, J., Ma, J., Gao, L., Wang, J., Zhang, D., Chen, L., Fang, J., Feng, T., & Wu, T. (2023) · npj Parkinson s Disease · doi:10.1038/s41531-023-00532-x · Cited by 33
Pyroptosis in neurodegenerative diseases: from bench to bedside
Wu, K., Wang, W.-R., Cheng, Q.-H., Li, H., Yan, W.-Z., Zhou, F.-R., & Zhang, R. (2023) · Cell Biology and Toxicology · doi:10.1007/s10565-023-09820-x · Cited by 32
NeuroVoz: a Castillian Spanish corpus of parkinsonian speech
Mendes-Laureano, J., Gómez-García, J. A., Guerrero-López, A., Luque‐Buzo, E., Arias-Londoño, J. D., Grandas, F., & Godino-Llorente, J. I. (2024) · Scientific Data · doi:10.1038/s41597-024-04186-z · Cited by 29
Zhang, P., Huang, P., Li, Y., Du, J., Luo, N., He, Y., Liu, J., He, G., Cui, S., Zhang, W., et al. (2024) · Aging and disease · doi:10.14336/ad.2023.0518 · Cited by 30
Lu, H., 南方医科大学南方医院神经内科, 广. 广. 5., Chai, J., Xu, Z., Wu, J., He, S., Liao, H., Huang, P., Huang, X., Chen, X., et al. (2023) · 动物学研究 · doi:10.24272/j.issn.2095-8137.2023.101 · Cited by 28
Protective mechanism of Paeonol on central nervous system
Wu, R., Liu, Y., Zhang, F., Dai, S., Xue, X., Peng, C., Li, Y., & Li, Y. (2023) · Phytotherapy Research · doi:10.1002/ptr.8049 · Cited by 27
Ning, P., Guo, X.-Z., Qu, Q.-M., & Li, R. (2023) · Environmental science and pollution research international · doi:10.1007/s11356-023-31047-w · Cited by 27
Jabbehdari, S., Oganov, A. C., Rezagholi, F., Mohammadi, S., Harandi, H., Yazdanpanah, G., & Arévalo, J. F. (2023) · Survey of Ophthalmology · doi:10.1016/j.survophthal.2023.11.003 · Cited by 30
Delivering the diagnosis of Parkinson's disease- setting the stage with hope and compassion
Subramanian, I., Pushparatnam, K., McDaniels, B. W., Mathur, S., Post, B., & Schrag, A. E. (2023) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2023.105926 · Cited by 28
Yao, Z., Jia, F., Wang, S., Jiao, Q., Du, X., Chen, X., & Jiang, H. F. (2024) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2024.06.020 · Cited by 29
Zhang, M., Xiang, C., Niu, R., He, X., Luo, W., Liu, W., & Gu, R. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-00048 · Cited by 34
Yao, H., Tong, W., Song, Y., Li, R., Xiang, X., Cheng, W., Zhou, Y., He, Y., Yang, Y., Liu, Y., et al. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03234-0 · Cited by 29
Huang, G., Liu, Y., Zhu, X., He, L., & Chen, T. (2025) · Exploration · doi:10.1002/exp.20240415 · Cited by 28
Neural network-assisted personalized handwriting analysis for Parkinson’s disease diagnostics
Chen, G., Tat, T., Zhou, Y., Duan, Z., Zhang, J., Scott, K., Zhao, X., Liu, Z., Wang, W. W., Li, S., et al. (2025) · Nature Chemical Engineering · doi:10.1038/s44286-025-00219-5 · Cited by 29
Recent advances in exosome-based nanodelivery systems for Parkinson's disease
Zhu, Y., Xi, Q., Liu, Y., Zhou, Y., Liao, J., & Wu, Q. (2025) · Biomaterials · doi:10.1016/j.biomaterials.2025.123548 · Cited by 37
Autophagy system as a potential therapeutic target for neurodegenerative diseases
Cui, M., Yoshimori, T., & Nakamura, S. (2022) · Neurochemistry International · doi:10.1016/j.neuint.2022.105308 · Cited by 29
Dysregulation of Human Somatic piRNA Expression in Parkinson’s Disease Subtypes and Stages
Zhang, T., & Wong, G. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23052469 · Cited by 29
Chua, S. K. K., Saffari, S. E., Lee, S. J. Y., & Tan, E. (2022) · Journal of Parkinson s Disease · doi:10.3233/jpd-223291 · Cited by 32
Chen, L., Huang, T., Ma, D., & Chen, Y. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.905121 · Cited by 28
Hao, Z., Zhang, X., & Chen, P. (2022) · Brain Sciences · doi:10.3390/brainsci12060698 · Cited by 34
Qin, Q., Wan, H., Wang, D., Li, J., Qu, Y., Zhao, J., Li, J., & Xue, Z. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.892493 · Cited by 29
Bhidayasiri, R., Phuenpathom, W., Tan, A. H., Leta, V., Phumphid, S., Chaudhuri, К. R., & Pal, P. K. (2022) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2022.979826 · Cited by 28
Trinh, J., Hicks, A. A., König, I. R., Delcambre, S., Lüth, T., Schaake, S., Wasner, K., Ghelfi, J., Borsche, M., Vilariño‐Güell, C., et al. (2022) · Brain · doi:10.1093/brain/awac464 · Cited by 27
Self-citationJin, Y., Wu, R., Li, L., Shen, L., Gu, Y., & Sun, C. (2023) · Molecular Neurobiology · doi:10.1007/s12035-022-03179-6 · Cited by 30
Chintalapudi, N., Dhulipalla, V. R., Battineni, G., Ruocco, C., & Amenta, F. (2023) · Journal of Data Science and Intelligent Systems · doi:10.47852/bonviewjdsis3202831 · Cited by 29
Li, H., Zhang, C., Zhang, K., Liu, Y.-Z., Peng, X., & Zong, Q. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1137366 · Cited by 28
Role of microglial metabolic reprogramming in Parkinson's disease
Huang, Z., Liu, S., Zhuang, J.-L., Li, L., Li, M.-M., Huang, Y., Chen, Y., Chen, X., Lin, S., Ye, L., et al. (2023) · Biochemical Pharmacology · doi:10.1016/j.bcp.2023.115619 · Cited by 31
Cai, D., Zhang, J., Wu, S., Zhang, L., Ma, Q., Wu, Z., Song, B., & Song, R. (2023) · Journal of Agricultural and Food Chemistry · doi:10.1021/acs.jafc.3c01132 · Cited by 28
Single-Cell Sequencing in Neurodegenerative Disorders
Pozojevic, J., & Spielmann, M. (2023) · Molecular Diagnosis & Therapy · doi:10.1007/s40291-023-00668-9 · Cited by 30
Catecholamine Derivatives: Natural Occurrence, Structural Diversity, and Biological Activity
Tang, K.-J., Zhao, Y., Tao, X., Li, J., Chen, Y., Holland, D. C., Jin, T., Wang, A.-Y., & Xiang, L. (2023) · Journal of Natural Products · doi:10.1021/acs.jnatprod.3c00465 · Cited by 29
Assessing the importance of primary care diagnoses in the UK Biobank
Clifton, L., Liu, X., Collister, J. A., Littlejohns, T. J., Allen, N. E., & Hunter, D. J. (2024) · European Journal of Epidemiology · doi:10.1007/s10654-023-01095-0 · Cited by 27
Advanced therapies in Parkinson’s disease: an individualized approach to their indication
Schröter, N., Sajonz, B., Jost, W. H., Rijntjes, M., Coenen, V. A., & Groppa, S. (2024) · Journal of Neural Transmission · doi:10.1007/s00702-024-02773-3 · Cited by 28
Yang, Y., Luo, S., Wang, W., Gao, X., Yao, X., & Wu, T. (2024) · NeuroImage Clinical · doi:10.1016/j.nicl.2024.103608 · Cited by 27
“Parkinson ’ s disease (PD) is a neurodegenerative disease that is characterized by dyskinesia and other symptoms (Bloem et al., 2021).”
Role of the globus pallidus in motor and non-motor symptoms of Parkinson’s disease
Jiang, Y., Qi, Z., Zhu, H., Shen, K., Liu, R., Fang, C., Lou, W., Jiang, Y.-F., Yuan, W.-R., Cao, X., et al. (2024) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-23-01660 · Cited by 30
DOPA-decarboxylase is elevated in CSF, but not plasma, in prodromal and de novo Parkinson’s disease
Appleton, E., Khosousi, S., Ta, M., Nalls, M. A., Singleton, A., Sturchio, A., Markaki, I., Pasławski, W., Iwaki, H., & Svenningsson, P. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00421-0 · Cited by 27
Herz, D. M., Frank, M. J., Tan, H., & Groppa, S. (2024) · Brain · doi:10.1093/brain/awae184 · Cited by 31
A review on polyamines as promising next-generation neuroprotective and anti-aging therapy
Arthur, R., Jamwal, S., & Kumar, P. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176804 · Cited by 30
Rusch, C. T., Beke, M., Nieves, C., Mai, V., Stiep, T., Tholanikunnel, T., Ramirez‐Zamora, A., Hess, C. W., & Langkamp‐Henken, B. (2024) · Nutrients · doi:10.3390/nu16172946 · Cited by 29
Molecular mechanism of PANoptosis and programmed cell death in neurological diseases
Hou, K., Pan, W., Liu, L.-Y., Yu, Q., Ou, J. T., Li, Y., Yang, X., Lin, Z., Yuan, J. H., & Fang, M. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106907 · Cited by 31
LRRK2-mediated mitochondrial dysfunction in Parkinson’s disease
Buck, S. A., & Sanders, L. H. (2025) · Biochemical Journal · doi:10.1042/bcj20253062 · Cited by 27
Screening of Parkinson’s Disease Using Geometric Features Extracted from Spiral Drawings
Chandra, J., Muthupalaniappan, S., Shang, Z., Deng, R., Lin, R., Tolkova, I., Butts, D., Sul, D., Marzouk, S., Bose, S., et al. (2021) · Brain Sciences · doi:10.3390/brainsci11101297 · Cited by 31
Metabolic Alterations in a Drosophila Model of Parkinson’s Disease Based on DJ-1 Deficiency
Solana‐Manrique, C., Sanz, F., Torregrosa, I., Palomino‐Schätzlein, M., Hernández-Oliver, C., Pineda‐Lucena, A., & Paricio, N. (2022) · Cells · doi:10.3390/cells11030331 · Cited by 24
Sorting Nexin 5 Plays an Important Role in Promoting Ferroptosis in Parkinson’s Disease
Huang, Z., Han, J., Wu, P., Wu, C., Fan, Y., Zhao, L., Hao, X., Chen, D., & Zhu, M. (2022) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2022/5463134 · Cited by 27
Applications and challenges of rhodopsin-based optogenetics in biomedicine
Zhang, H., Fang, H., Liu, D., Zhang, Y., Adu‐Amankwaah, J., Yuan, J., Tan, R., & Zhu, J. (2022) · Frontiers in Neuroscience · doi:10.3389/fnins.2022.966772 · Cited by 27
Li, J., Li, N., Wei, J., Feng, C. L., Chen, Y., Chen, T., Ai, Z., Zhu, X., Ji, W., & Li, T. (2022) · npj Parkinson s Disease · doi:10.1038/s41531-022-00440-6 · Cited by 28
Cerebral Small Vessel Disease Progression Increases Risk of Incident Parkinsonism
Jacob, M. A., Cai, M., Bergkamp, M. I., Darweesh, S. K. L., Gelissen, L. M. Y., Marques, J. P., Norris, D. G., Duering, M., Esselink, R. A. J., Tuladhar, A. M., et al. (2023) · Annals of Neurology · doi:10.1002/ana.26615 · Cited by 27
Characteristics of fatigue in Parkinson’s disease: A longitudinal cohort study
Zhou, X., Xiang, Y., Song, T., Zhao, Y., Pan, H., Xu, Q., Chen, Y., Sun, Q., Wu, X., Yan, X., et al. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1133705 · Cited by 27
Diagnosis of Parkinson's Disease via the Metabolic Fingerprint in Saliva by Deep Learning
Xu, W., Chen, L., Cai, G., Gao, M. Y., Chen, Y., Pu, J., Chen, X., Liu, N., Ye, Q., & Qian, K. (2023) · Small Methods · doi:10.1002/smtd.202300285 · Cited by 29
NFE2L1/Nrf1 serves as a potential therapeutical target for neurodegenerative diseases
Łuczyńska, K., Zhang, Z., Pietras, T., Zhang, Y., & Taniguchi, H. (2023) · Redox Biology · doi:10.1016/j.redox.2023.103003 · Cited by 32
Automating the analysis of eye movement for different neurodegenerative disorders
Li, D., Butala, A., Moro-Velázquez, L., Meyer, T., Oh, E. S., Motley, C., Villalba, J., & Dehak, N. (2024) · Computers in Biology and Medicine · doi:10.1016/j.compbiomed.2024.107951 · Cited by 31
Extracellular vesicles as nanotheranostic platforms for targeted neurological disorder interventions
Choi, H. K., Chen, M., Goldston, L. L., & Lee, K.-B. (2024) · Nano Convergence · doi:10.1186/s40580-024-00426-5 · Cited by 26
Flores‐Torres, M. H., Christine, C. W., Bjørnevik, K., Molsberry, S. A., Hung, A. Y., Healy, B. C., Blacker, D., Schwarzschild, M. A., & Ascherio, A. (2023) · Movement Disorders · doi:10.1002/mds.29383 · Cited by 27
Early-stage idiopathic Parkinson’s disease is associated with reduced circular RNA expression
Whittle, B. J., Izuogu, O. G., Lowes, H., Deen, D., Pyle, A., Coxhead, J., Lawson, R. A., Yarnall, A. J., Jackson, M. S., Santibanez‐Koref, M., et al. (2024) · npj Parkinson s Disease · doi:10.1038/s41531-024-00636-y · Cited by 25
Cai, B., Wang, Q., Zhong, L., Liu, F., Wang, X., & Chen, T. (2024) · Drug Design Development and Therapy · doi:10.2147/dddt.s462333 · Cited by 26
A lipid droplet-targeted NIR fluorescent probe for viscosity detection in Parkinson's disease
Ma, S., Li, L., Wan, P., Li, L., Huang, Z., Yu, Q., Zhang, B., Guo, L., Yan, L., Li, L., et al. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.136441 · Cited by 26
Li, J., Song, J., Jia, L., Wang, M., Ji, X., Meng, R., & Zhou, D. (2024) · Biomolecules · doi:10.3390/biom14121519 · Cited by 28
GLP‐1 receptor agonists for Parkinson's disease: An updated meta-analysis
de Albuquerque, M. B., Nunes, L. E. D. B., Maldonado, J. V. D. O., Ferreira, D. G. M., Margato, M. M., Rabelo, L. V., Valênça, M. M., & Cordeiro, L. H. O. (2024) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2024.107220 · Cited by 26
Wang, G., Zhou, X., Pang, X., Ma, K., Li, L., Song, Y., Hou, D., & Wang, X. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1625821 · Cited by 28
Yalçın, M., Grande, V., Outeiro, T. F., & Relógio, A. (2025) · npj Parkinson s Disease · doi:10.1038/s41531-025-01009-9 · Cited by 32
Proteolytic α-Synuclein Cleavage in Health and Disease
Bluhm, A., Schrempel, S., von Hörsten, S., Schulze, A., & Roßner, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115450 · Cited by 26
Haghshomar, M., Shobeiri, P., Seyedi, S. A., Abbasi-Feijani, F., Poopak, A., Sotoudeh, H., Kamali, A., & Aarabi, M. H. (2022) · The Cerebellum · doi:10.1007/s12311-021-01355-3 · Cited by 27
The Therapeutic Potential of Secreted Factors from Dental Pulp Stem Cells for Various Diseases
Ogata, K., Moriyama, M., Matsumura‐Κawashima, M., Kawado, T., Yano, A., & Nakamura, S. (2022) · Biomedicines · doi:10.3390/biomedicines10051049 · Cited by 26
Dang, X., Zhang, Z., & Luo, X. (2022) · Movement Disorders · doi:10.1002/mds.29239 · Cited by 25
Parkinson’s Disease Wearable Gait Analysis: Kinematic and Dynamic Markers for Diagnosis
di Biase, L., Raiano, L., Caminiti, M. L., Pecoraro, P. M., & Lazzaro, V. D. (2022) · Sensors · doi:10.3390/s22228773 · Cited by 26
Immune Modulatory Effects of Ketogenic Diet in Different Disease Conditions
Srivastava, S., Pawar, V. A., Tyagi, A., Sharma, K., Kumar, V., & Shukla, S. K. (2022) · Immuno · doi:10.3390/immuno3010001 · Cited by 26
Palomba, N. P., Fortunato, G., Pepe, G., Modugno, N., Pietracupa, S., Damiano, I., Mascio, G., Carrillo, F., Giovannantonio, L. G. D., Ianiro, L., et al. (2023) · Molecular Neurobiology · doi:10.1007/s12035-022-03203-9 · Cited by 27
Huang, B., Hu, G., Zong, X., Yang, S., He, D., Gao, X., & Liu, D. (2023) · International Immunopharmacology · doi:10.1016/j.intimp.2023.109698 · Cited by 26
Gasparotto, J., Somensi, N., Girardi, C. S., Bittencourt, R. R., de Oliveira, L. M., Hoefel, L. P. L., Scheibel, I. M., Peixoto, D. O., Moreira, J. C. F., Outeiro, T. F., et al. (2023) · Journal of Neurochemistry · doi:10.1111/jnc.15890 · Cited by 27
Al-Nefaie, A. H. A., Aldhyani, T. H. H., & Koundal, D. (2024) · Journal of Disability Research · doi:10.57197/jdr-2024-0001 · Cited by 26
Characterization of graded 6-Hydroxydopamine unilateral lesion in medial forebrain bundle of mice
Cui, J., Zhao, D., Xu, M., Li, Z., Qian, J., Song, N., Wang, J., & Xie, J. (2024) · Scientific Reports · doi:10.1038/s41598-024-54066-0 · Cited by 26
Salivary Biomarkers for Parkinson’s Disease: A Systematic Review with Meta-Analysis
Nijakowski, K., Owecki, W., Jankowski, J., & Surdacka, A. (2024) · Cells · doi:10.3390/cells13040340 · Cited by 27
Proietti, T., & Bandini, A. (2024) · IEEE Transactions on Neural Systems and Rehabilitation Engineering · doi:10.1109/tnsre.2024.3435042 · Cited by 26
Interpretable video-based tracking and quantification of Parkinsonism clinical motor states
Deng, D., Ostrem, J. L., Nguyen, V., Cummins, D. D., Sun, J., Pathak, A., Little, S., & Abbasi-Asl, R. (2024) · npj Parkinson's Disease · doi:10.1038/s41531-024-00742-x · Cited by 25
Cui, X., Zhou, Y., Zhao, C., Li, J., Zheng, X., Li, X., Shan, S., Liu, J., & Liu, X. (2023) · IEEE Transactions on Instrumentation and Measurement · doi:10.1109/tim.2023.3315407 · Cited by 25
Artificial Intelligence in The Management of Neurodegenerative Disorders
Dhankhar, S., Mujwar, S., Garg, N., Chauhan, S., Saini, M., Sharma, P., Kumar, S., Sharma, S. K., Kamal, M. A., & Rani, N. (2023) · CNS & Neurological Disorders - Drug Targets · doi:10.2174/0118715273266095231009092603 · Cited by 26
Walker, R. W., Fothergill‐Misbah, N., Kariuki, S., Ojo, O. O., Cilia, R., Dekker, M. C. J., Agabi, O. P., Akpalu, A. K., Amod, F. C., Breckons, M., et al. (2023) · BMC Neurology · doi:10.1186/s12883-023-03414-0 · Cited by 27
Wang, Y., Yang, W., Cao, J., Liu, Y., Shao, M., Xu, X., & Chen, H. (2024) · Sensors and Actuators B Chemical · doi:10.1016/j.snb.2024.136066 · Cited by 25
Metadata
- Authors
- Bloem, B. R., Okun, M. S., & Klein, C.
- Affiliations
- Radboud University Nijmegen (NL)
- University of Florida Health (US)
- University Hospital Schleswig-Holstein (DE)
- Corresponding author
- Bloem, Bastiaan R
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2021-06
- Volume
- 397
- Issue
- 10291
- Pages
- 2284-2303
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4206481149
- Cited by
- 3,920
- References
- 159
- Citations by year
- 2026: 878 · 2025: 1098 · 2024: 901 · 2023: 607 · 2022: 364 · 2021: 72
- FWCI
- 62.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion)
- PubMed (publishedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion, other-oa)
- Funders
- Deutsche Forschungsgemeinschaft
- Parkinson's Foundation (FOR2488)
- Topics
- Health Sciences › Medicine › Clinical Neurology › Parkinson's Disease Mechanisms and Treatments
- Health Sciences › Medicine › Clinical Neurology › Deep Brain Stimulation and Movement Disorders
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Keywords
- Parkinson's disease, neurodegeneration, genetic risk variants, monogenic Parkinson's disease, non-motor symptoms, levodopa, disease-modifying therapy, multidisciplinary care, non-pharmacological treatment, diagnosis, prodromal period
- MeSH terms
- Antiparkinson Agents, Humans, Levodopa, Parkinson Disease, Time Factors, Tremor, Disease Management, Prodromal Symptoms
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
